Literature DB >> 20089498

Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content.

David A Bushinsky1.   

Abstract

Calcium (Ca) balance is the net of Ca intake and output from the body over a period of time. The concept of Ca balance does not consider the redistribution of Ca that often occurs in patients with chronic kidney disease (CKD), especially those who are on dialysis, which is often in the form of soft tissue and/or vascular calcification. In this article, we consider movement of Ca with respect to the extracellular fluid (ECF) and develop a mathematical formulation for Ca homeostasis with respect to the ECF that includes input and output from the diet, the bone, the kidney, and dialysis. We consider calcium homeostasis in healthy individuals and in patients with excess parathyroid hormone, excess 1,25-dihydroxyvitamin D(3), and metabolic acidosis; patients who have CKD and are not on dialysis; and, finally, patients who have CKD and are on dialysis. On the basis of a number of assumptions, dialysis patients with a daily intake of >37.5 mmol of elemental Ca (1.5 g) have movement of Ca into the ECF even without supplemental activated vitamin D. Addition of activated vitamin D, which increases intestinal Ca absorption and can increase resorption of Ca from bone, leads to the movement of Ca into the ECF at virtually all levels of intake; however, there are numerous unanswered questions regarding Ca homeostasis in patients with CKD, including how much of the Ca, administered as a phosphate binder, is absorbed and what is the fate of this absorbed Ca. Until these pressing questions are answered with well-designed experiments, we do not know whether we are doing more harm than good for our dialysis patients by administering additional Ca as a phosphate binder, especially when they also receive activated vitamin D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089498     DOI: 10.2215/CJN.05970809

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  20 in total

Review 1.  Mineral and bone disorders in children with chronic kidney disease.

Authors:  Claus Peter Schmitt; Otto Mehls
Journal:  Nat Rev Nephrol       Date:  2011-09-27       Impact factor: 28.314

2.  Mineral metabolism: The perils of a falling PTH due to high dialysate calcium.

Authors:  Wei Chen; David A Bushinsky
Journal:  Nat Rev Nephrol       Date:  2016-03-21       Impact factor: 28.314

Review 3.  Hyperphosphataemia: treatment options.

Authors:  Fabio Malberti
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

4.  Calcium fluxes at the bone/plasma interface: Acute effects of parathyroid hormone (PTH) and targeted deletion of PTH/PTH-related peptide (PTHrP) receptor in the osteocytes.

Authors:  Christopher Dedic; Tin Shing Hung; Alan M Shipley; Akira Maeda; Thomas Gardella; Andrew L Miller; Paola Divieti Pajevic; Joseph G Kunkel; Alessandro Rubinacci
Journal:  Bone       Date:  2018-07-24       Impact factor: 4.398

5.  Macrophage-stimulating protein and calcium homeostasis in zebrafish.

Authors:  Leonie F A Huitema; Jörg Renn; Ive Logister; Jerilyn K Gray; Susan E Waltz; Gert Flik; Stefan Schulte-Merker
Journal:  FASEB J       Date:  2012-07-11       Impact factor: 5.191

6.  Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Authors:  Kevin K Frick; John R Asplin; Murray J Favus; Christopher Culbertson; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-23

Review 7.  Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.

Authors:  Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino
Journal:  Clin J Am Soc Nephrol       Date:  2015-07-29       Impact factor: 8.237

Review 8.  Calcium balance and negative impact of calcium load in peritoneal dialysis patients.

Authors:  Angela Yee-Moon Wang
Journal:  Perit Dial Int       Date:  2014-02-04       Impact factor: 1.756

9.  Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.

Authors:  David A Bushinsky; David M Spiegel; Jinwei Yuan; Suzette Warren; Jeanene Fogli; Pablo E Pergola
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-31       Impact factor: 8.237

10.  Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study.

Authors:  Matteo Ruggeri; Antonio Bellasi; Filippo Cipriani; Donald Molony; Cynthia Bell; Domenico Russo; Biagio Di Iorio
Journal:  J Nephrol       Date:  2014-07-16       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.